8-K: Firefly Neuroscience Completes Merger, Set to Trade on Nasdaq as AIFF

Firefly Neuroscience has finalized its merger with WaveDancer, Inc., and will commence trading on the Nasdaq under the ticker symbol AIFF on August 13, 2024.

Summary

• Firefly Neuroscience, Inc. has successfully completed its merger with WaveDancer, Inc.
• The combined company will trade on the Nasdaq Capital Market under the ticker symbol AIFF starting August 13, 2024.
• Firefly stockholders now own approximately 92% of the combined company, while former WaveDancer stockholders own about 8%.
• A concurrent private placement raised approximately $3.5 million in gross proceeds for the company.
• The company intends to use the funds for working capital and general corporate purposes.
• The merger involved a reverse stock split at a ratio of 1-for-3, which reduced the number of outstanding shares of WaveDancer common stock from 2,013,180 to approximately 671,060.
• The new CUSIP number for the common stock following the reverse stock split is 317970101.
• The merger was completed on August 12, 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful completion of the merger, the concurrent capital raise, and the company's focus on commercialization. However, the risks associated with the business combination and the company's limited operating history temper the overall optimism.

Positives

• The merger provides Firefly with access to public markets and additional capital.
• The private placement provides immediate funding for working capital and general corporate purposes.
• The combined company will focus on developing and commercializing Firefly's BNA platform.
• The company has a clear path to commercialization of its BNA platform.

Negatives

• The reverse stock split reduced the number of outstanding shares, which may impact share price.
• The company is still in the early stages of commercialization and may face challenges in achieving profitability.

Risks

• The company may not be able to successfully commercialize its BNA platform.
• The company may not be able to obtain sufficient additional capital to continue to advance its products, clinical and pharmaceutical programs.
• The company may face challenges in protecting its intellectual property rights.
• The company may face competitive responses to the business combination.
• The company may experience unexpected costs, charges or expenses resulting from the business combination.
• The company may experience potential adverse reactions or changes to business relationships resulting from the completion of the business combination.
• The company may be impacted by legislative, regulatory, political and economic developments.
• The company may experience fluctuation and volatility in market price of the combined companys common stock due to market and industry factors, as well as general economic, political and market conditions.
• The company may experience the impact of dilution on the stockholders of the combined company, including through the issuance of additional equity securities in the future.
• The company may not be able to realize the intended benefits of the merger.
• The company may not be able to realize the anticipated tax impact of the merger.
• The company may become subject to litigation or other proceedings in the future.
• The company may experience delisting of the New Firefly Common Stock from the Nasdaq or the failure for an active trading market to develop.
• The company may experience the failure of altered business operations, strategies and focus of the combined company to result in an improvement for the value of New Firefly Common Stock.
• The company may not be able to continue to obtain sufficient funding to conduct planned operations and realize potential profits.
• The company has a limited operating history.
• The company may be impacted by the complexity of the regulatory landscape on the Companys ability to seek and obtain regulatory approval for its BNA Platform, both within and outside of the U.S.
• The company may face challenges with maintaining regulatory approval, if achieved.
• The company may be impacted by the concertation of capital stock ownership with insiders of the combined company after the merger on stockholders ability to influence corporate matters.
• The company may experience the impacts of future acquisitions of businesses or products and the potential to fail to realize intended benefits of such acquisition.
• The company may be impacted by changes in the legal and regulatory landscape, both within and outside of the U.S.
• The company is dependent on third parties.
• The company may face challenges with respect to its BNA Platform achieving market acceptance.
• The company may be impacted by the pricing of the Companys BNA Platform.
• The company may face emerging competition and rapidly advancing technology in the Companys industry.
• The company may not be able to obtain, maintain and protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on its proprietary rights.
• The company may not be able to maintain adequate cyber security and information systems.

Future Outlook

The combined company will focus on developing and commercializing Firefly's BNA platform and is preparing its commercialization strategy to transform the standard of care for brain health.

Management Comments

• By harnessing the power of AI through our BNA technology platform, we can provide neurologists and their patients with an objective measurement of their brain activity to more accurately support diagnosis, assess treatment efficacy, increase patient compliance and track disease progression and ultimately improve patient outcomes.
• With the closing of our merger and additional working capital, we are preparing our commercialization strategy to transform the standard of care for brain health.

Industry Context

The merger positions Firefly to capitalize on the growing need for advanced diagnostic and treatment approaches for mental illnesses and cognitive disorders, leveraging its AI-driven BNA platform.

Comparison to Industry Standards

• The BNA platform is a software as a medical solution (SAMS) that was developed using artificial intelligence (AI) and machine learning on Fireflys extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEG) of over 17,000 patients representing twelve disorders, as well as clinically normal patients.
• The BNA platform is a unique offering in the market, as it provides clinicians with comprehensive insights into brain function (cognition) by comparing a patients brain function to that of a clinically normal age-matched patient.
• The BNA platform has demonstrated improved response rates, enhanced therapy compliance, reduced non-responder rates and a reduction in need for medication switching among patients.
• The BNA platform is a unique offering in the market, as it provides clinicians with comprehensive insights into brain function (cognition) by comparing a patients brain function to that of a clinically normal age-matched patient.
• The BNA platform has demonstrated improved response rates, enhanced therapy compliance, reduced non-responder rates and a reduction in need for medication switching among patients.
• The BNA platform is a unique offering in the market, as it provides clinicians with comprehensive insights into brain function (cognition) by comparing a patients brain function to that of a clinically normal age-matched patient.
• The BNA platform has demonstrated improved response rates, enhanced therapy compliance, reduced non-responder rates and a reduction in need for medication switching among patients.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders of Firefly will own approximately 92% of the combined company.
• Shareholders of WaveDancer will own approximately 8% of the combined company.
• The company intends to use the net proceeds of the private placement for working capital and general corporate purposes, which may benefit employees and other stakeholders.
• The company's focus on commercializing the BNA platform may lead to improved patient outcomes.

Next Steps

• The combined company will focus on developing and commercializing Firefly's BNA platform.
• The company will prepare its commercialization strategy to transform the standard of care for brain health.

Key Dates

Keywords

Merger, Firefly Neuroscience, WaveDancer, Nasdaq, AIFF, Reverse Stock Split, Brain Network Analytics, BNA Platform, Private Placement, Neuroscience, Mental Illness, Cognitive Disorders